Palumbo Wealth Management LLC Invests $275,000 in Dynavax Technologies Co. (NASDAQ:DVAX)

Palumbo Wealth Management LLC acquired a new stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,533 shares of the biopharmaceutical company's stock, valued at approximately $275,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE lifted its holdings in Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 2,034 shares during the period. Capital Performance Advisors LLP bought a new stake in Dynavax Technologies during the third quarter valued at $45,000. Nisa Investment Advisors LLC grew its holdings in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock worth $61,000 after acquiring an additional 1,679 shares during the period. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Dynavax Technologies during the 4th quarter worth about $71,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Stock Up 1.2 %

DVAX stock traded up $0.16 during trading on Wednesday, reaching $13.09. 2,890,284 shares of the stock were exchanged, compared to its average volume of 1,789,610. The firm's 50 day moving average is $12.80 and its 200 day moving average is $11.98. The firm has a market cap of $1.72 billion, a P/E ratio of 100.70 and a beta of 1.32. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $13.89.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright boosted their price objective on Dynavax Technologies from $29.00 to $31.00 and gave the company a "buy" rating in a research note on Tuesday, January 14th. StockNews.com cut Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group downgraded shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.